Masanori Kurihara

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

Journal: medRxiv : the preprint server for health sciences

Published: July 03, 2026

MMSE-CDR-SB residual as an exploratory indicator of deviation from an Alzheimer's disease-typical cognitive-functional pattern.

MMSE-CDR-SB residual as an exploratory indicator of deviation from an Alzheimer's disease-typical cognitive-functional pattern.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: May 23, 2026

Early-onset Alzheimer's disease with PSEN1 G206D mutation presenting with amnesia at an onset age of 29 years old

Early-onset Alzheimer's disease with PSEN1 G206D mutation presenting with amnesia at an onset age of 29 years old

Journal: Rinsho shinkeigaku = Clinical neurology

Published: April 12, 2026

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: February 27, 2026

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

Journal: The journal of prevention of Alzheimer's disease

Published: January 20, 2026

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.

Journal: The journal of prevention of Alzheimer's disease

Published: January 11, 2026

Relapses, Comorbidities, and Predictors of Outcome in Anti-GABAA Receptor Encephalitis.

Relapses, Comorbidities, and Predictors of Outcome in Anti-GABAA Receptor Encephalitis.

Journal: Annals of neurology

Published: December 18, 2025

Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.

Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.

Journal: Journal of neurochemistry

Published: December 11, 2025

Persistent Bilateral [18F]THK5351 and Migrating Unilateral [18F]FDG Uptake in Anti-LGI1 Encephalitis.

Persistent Bilateral [18F]THK5351 and Migrating Unilateral [18F]FDG Uptake in Anti-LGI1 Encephalitis.

Journal: Annals of clinical and translational neurology

Published: December 05, 2025

Utility of APOE testing for reducing ARIA under probabilistic stopping rates to treat with anti-amyloid therapy for ε4-homozygote patients: A simulation study.

Utility of APOE testing for reducing ARIA under probabilistic stopping rates to treat with anti-amyloid therapy for ε4-homozygote patients: A simulation study.

Journal: JAR life

Published: December 01, 2025

Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform.

Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform.

Journal: Alzheimer's research & therapy

Published: November 14, 2025

National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in Japan.

National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in Japan.

Journal: Journal of Alzheimer's disease reports

Published: September 14, 2025

Showing 1-12 of 54

Last Updated: 09/26/2026